Girentuximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Girentuximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric
Target CA-IX
Clinical data
Trade names Rencarex
Legal status
?
Identifiers
CAS number 916138-87-9 N
ATC code None
UNII 539B57DFJF YesY
Chemical data
Formula C6460H10006N1718O2018S48 
Mol. mass 146.5 kDa
 N (what is this?)  (verify)

Girentuximab (trade name Rencarex) is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.[1]

Girentuximab was developed by Wilex AG.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Girentuximab". American Medical Association.